Cargando…

Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia

BACKGROUND: Pain is a main symptom of herpes zoster (HZ), and postherpetic neuralgia (PHN) is a frequent complication occurring in 5% to 15% of cases, causing moderate to severe neuropathic pain. A population-based observational study was conducted to evaluate the treatment patterns and economic bur...

Descripción completa

Detalles Bibliográficos
Autores principales: Friesen, Kevin J, Falk, Jamie, Alessi-Severini, Silvia, Chateau, Dan, Bugden, Shawn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976915/
https://www.ncbi.nlm.nih.gov/pubmed/27536159
http://dx.doi.org/10.2147/JPR.S107944
_version_ 1782446937402769408
author Friesen, Kevin J
Falk, Jamie
Alessi-Severini, Silvia
Chateau, Dan
Bugden, Shawn
author_facet Friesen, Kevin J
Falk, Jamie
Alessi-Severini, Silvia
Chateau, Dan
Bugden, Shawn
author_sort Friesen, Kevin J
collection PubMed
description BACKGROUND: Pain is a main symptom of herpes zoster (HZ), and postherpetic neuralgia (PHN) is a frequent complication occurring in 5% to 15% of cases, causing moderate to severe neuropathic pain. A population-based observational study was conducted to evaluate the treatment patterns and economic burden of prescription drug treatment of HZ and PHN pain in the province of Manitoba (Canada) over a period of 15 years. METHODS: Administrative health care data, including medical and hospital separation records, were examined to identify episodes of HZ using International Classification of Diseases-9/10 codes between April 1, 1997 and March 31, 2014. Episodes of PHN were identified using medical and prescription claims. Incident use of analgesic, antidepressant, or anticonvulsant drugs was used to determine prescription pain costs. RESULTS: The age-adjusted incidence of HZ increased from 4.7 episodes/1,000 person-years in 1997/98 to 5.7/1,000 person-years in 2013/14. PHN occurred in 9.2% of HZ cases, a rate that did not change over the study period (P=0.57). The annual cost to treat HZ pain rose by 174% from 1997/98, reaching CAD $332,981 in 2011/12, 82.8% (95% confidence interval [CI] 81.2%, 84.3%) of which was related to PHN. The per episode cost of HZ rose by 111% from $31.59 (95% CI $25.35, $37.84) to $66.81 (95% CI $56.84, $76.78) and by 94% for PHN from $292 (95% CI $225, $358) to $566 (95% CI $478, $655). These increases were driven by increasing use of anticonvulsants, primarily gabapentin, which accounted for 57% of the increase in cost. CONCLUSION: There has been an increase in the incidence of HZ and PHN and in the average cost associated with the prescription treatment of their resultant neuropathic pain. The primary driver of the increased episodic cost is the increased use of gabapentin. These changes have resulted in a substantial increase in the economic burden associated with HZ and PHN.
format Online
Article
Text
id pubmed-4976915
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-49769152016-08-17 Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia Friesen, Kevin J Falk, Jamie Alessi-Severini, Silvia Chateau, Dan Bugden, Shawn J Pain Res Original Research BACKGROUND: Pain is a main symptom of herpes zoster (HZ), and postherpetic neuralgia (PHN) is a frequent complication occurring in 5% to 15% of cases, causing moderate to severe neuropathic pain. A population-based observational study was conducted to evaluate the treatment patterns and economic burden of prescription drug treatment of HZ and PHN pain in the province of Manitoba (Canada) over a period of 15 years. METHODS: Administrative health care data, including medical and hospital separation records, were examined to identify episodes of HZ using International Classification of Diseases-9/10 codes between April 1, 1997 and March 31, 2014. Episodes of PHN were identified using medical and prescription claims. Incident use of analgesic, antidepressant, or anticonvulsant drugs was used to determine prescription pain costs. RESULTS: The age-adjusted incidence of HZ increased from 4.7 episodes/1,000 person-years in 1997/98 to 5.7/1,000 person-years in 2013/14. PHN occurred in 9.2% of HZ cases, a rate that did not change over the study period (P=0.57). The annual cost to treat HZ pain rose by 174% from 1997/98, reaching CAD $332,981 in 2011/12, 82.8% (95% confidence interval [CI] 81.2%, 84.3%) of which was related to PHN. The per episode cost of HZ rose by 111% from $31.59 (95% CI $25.35, $37.84) to $66.81 (95% CI $56.84, $76.78) and by 94% for PHN from $292 (95% CI $225, $358) to $566 (95% CI $478, $655). These increases were driven by increasing use of anticonvulsants, primarily gabapentin, which accounted for 57% of the increase in cost. CONCLUSION: There has been an increase in the incidence of HZ and PHN and in the average cost associated with the prescription treatment of their resultant neuropathic pain. The primary driver of the increased episodic cost is the increased use of gabapentin. These changes have resulted in a substantial increase in the economic burden associated with HZ and PHN. Dove Medical Press 2016-08-03 /pmc/articles/PMC4976915/ /pubmed/27536159 http://dx.doi.org/10.2147/JPR.S107944 Text en © 2016 Friesen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Friesen, Kevin J
Falk, Jamie
Alessi-Severini, Silvia
Chateau, Dan
Bugden, Shawn
Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia
title Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia
title_full Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia
title_fullStr Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia
title_full_unstemmed Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia
title_short Price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia
title_sort price of pain: population-based cohort burden of disease analysis of medication cost of herpes zoster and postherpetic neuralgia
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976915/
https://www.ncbi.nlm.nih.gov/pubmed/27536159
http://dx.doi.org/10.2147/JPR.S107944
work_keys_str_mv AT friesenkevinj priceofpainpopulationbasedcohortburdenofdiseaseanalysisofmedicationcostofherpeszosterandpostherpeticneuralgia
AT falkjamie priceofpainpopulationbasedcohortburdenofdiseaseanalysisofmedicationcostofherpeszosterandpostherpeticneuralgia
AT alessiseverinisilvia priceofpainpopulationbasedcohortburdenofdiseaseanalysisofmedicationcostofherpeszosterandpostherpeticneuralgia
AT chateaudan priceofpainpopulationbasedcohortburdenofdiseaseanalysisofmedicationcostofherpeszosterandpostherpeticneuralgia
AT bugdenshawn priceofpainpopulationbasedcohortburdenofdiseaseanalysisofmedicationcostofherpeszosterandpostherpeticneuralgia